Sagimet Biosciences Inc. reported second-quarter 2026 results and pipeline progress focused on dermatology. For the quarter ended June 30, 2026, the company recorded a net loss of $13.9 million, compared with $10.4 million a year earlier, as it increased R&D investment.
Research and development expense was $11.5 million versus $7.2 million, while general and administrative expense was broadly flat at $4.3 million. A March–April 2026 equity financing generated $175.0 million of gross proceeds, lifting cash, cash equivalents and marketable securities to $257.6 million as of June 30, 2026, which Sagimet expects to fund operations through 2028, including Phase 3 denifanstat acne data readout and NDA submission.
Denifanstat met all primary and secondary endpoints in a Phase 3 acne trial in China, where an NDA was accepted in December 2025. Sagimet plans a U.S. registrational Phase 3 acne trial in the second half of 2026 and is running a first-in-human Phase 1 trial of follow-on FASN inhibitor TVB-3567.
Sagimet Biosciences Inc. reported a net loss of $13.9 million for the quarter ended June 30, 2026, compared with $10.4 million a year earlier, as it advanced its fatty acid synthase (FASN) inhibitor pipeline. For the first six months of 2026, net loss was $24.6 million versus $28.6 million in 2025, reflecting lower year-to-date research and development spending.
Cash, cash equivalents and marketable securities totaled $257.6 million at June 30, 2026, up sharply from $116.5 million in total assets at year-end 2025, driven by an April 2026 underwritten offering of 29,166,700 Series A shares at $6.00 per share, providing $163.9 million in net proceeds. Total assets were $263.4 million and stockholders’ equity was $256.2 million, with minimal liabilities.
Management expects existing liquidity to fund operating expenses for at least 12 months. The company remains a clinical-stage biotech with no product revenue, focusing on lead candidate denifanstat for acne and MASH, and TVB-3567 in a Phase 1 acne trial, while MASH combination work will not move beyond Phase 2 readiness without non-dilutive funding.
BlackRock, Inc. reports a passive ownership position in Sagimet Biosciences Inc. (Class A Stock) on a Schedule 13G. As of June 30, 2026, BlackRock’s reporting business units beneficially owned 4,751,186 Class A shares, representing 7.8% of the class.
BlackRock has sole voting power over 4,690,270 shares and sole dispositive power over all 4,751,186 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Sagimet’s outstanding common shares.
Sagimet Biosciences Inc. President & CEO David Happel sold 64,051 shares of Series A Common Stock on July 20, 2026 at a weighted average price of $7.7605 per share to cover tax withholding obligations from vesting restricted stock units. These automatic, non-discretionary sales occurred in multiple trades between $7.76 and $7.94 and left him holding 741,570 shares directly.
Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek sold 10,545 shares of Series A Common Stock on July 20, 2026, at a weighted average price of $7.7603 per share in transactions between $7.76 and $7.88.
The report states that these shares were automatically sold to cover tax withholding obligations related to vesting restricted stock units and were not at Rozek’s discretion. After these sales, she directly holds 224,414 shares of Sagimet stock.
George Kemble, a director of Sagimet Biosciences Inc., sold 18,844 shares of Series A Common Stock on July 20, 2026, at a weighted average price of $7.4575 per share in open-market or private transactions under a Rule 10b5-1 trading plan adopted on August 21, 2025. After these sales, he directly holds 62,161 shares. The reported trades occurred at prices ranging from $7.17 to $7.97 per share.
Sagimet Biosciences Inc. furnished an updated investor presentation describing its strategy around fatty acid synthase (FASN) inhibition in dermatology and metabolic disease. Lead oral FASN inhibitor denifanstat showed proof-of-concept in multiple settings, including a Phase 3 acne trial in China that met all primary and secondary endpoints and supported a denifanstat new drug application accepted by the China NMPA in December 2025.
The company plans a US Phase 3 trial of denifanstat in moderate to severe acne in the second half of 2026, contingent on regulatory consultation, and highlights a completed Phase 2b trial in MASH that met histology primary and multiple secondary endpoints and received FDA Breakthrough Therapy designation. Follow-on FASN inhibitor TVB-3567 is in a first-in-human Phase 1 study begun June 2025, with a Phase 2 acne trial anticipated in 2026, subject to regulatory feedback.
Sagimet reports intellectual property coverage for denifanstat and TVB-3567 extending into the 2030s and beyond. It cites $104 of cash, cash equivalents and marketable securities as of March 31, 2026 and an announced $175M underwritten Series A common stock offering in April 2026, which together are expected to fund operations through 2028 and through the planned denifanstat US Phase 3 acne readout.
Sagimet Biosciences director Beth C. Seidenberg received a grant of stock options covering 39,567 shares of Series A common stock on June 12, 2026. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
These options were awarded as a compensation grant, not a market purchase or sale. According to the terms, the underlying shares will vest in twelve equal monthly installments after June 12, 2026, as long as she continues serving the company on each vesting date.
Sagimet Biosciences Inc. director Paul W. Hoelscher received a grant of stock options covering 39,567 shares of Series A Common Stock. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
The award was granted at no cost to him and is structured as compensation, not an open-market trade. The underlying 39,567 shares will vest in twelve equal monthly installments beginning on June 12, 2026, subject to his continued service.